Rhumbline Advisers reduced its stake in Biogen Inc. by 3.6% in the third quarter, now holding 289,206 shares valued at $40.51 million. Despite a 7.2% year-over-year revenue decline, Biogen surpassed quarterly earnings estimates and provided optimistic FY2026 guidance. Institutional ownership remains high at 87.93%, with several major investment firms adjusting their positions, and analysts have issued various ratings for the stock.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Rhumbline Advisers Has $40.51 Million Position in Biogen Inc. $BIIB
Rhumbline Advisers reduced its stake in Biogen Inc. by 3.6% in the third quarter, now holding 289,206 shares valued at $40.51 million. Despite a 7.2% year-over-year revenue decline, Biogen surpassed quarterly earnings estimates and provided optimistic FY2026 guidance. Institutional ownership remains high at 87.93%, with several major investment firms adjusting their positions, and analysts have issued various ratings for the stock.